Boehringer Ingelheim has received EU approval for its Viramune (nevirapine) prolonged-release once-daily formulation, indicated for the treatment of HIV-1 infection.
The approval is based on results from clinical trials that confirmed the therapeutic benefits of nevirapine when administered in a once-daily formulation.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The VERxVE trial evaluated the antiviral efficacy and safety of once-daily nevirapine 400mg compared to twice-daily nevirapine 200mg.
The TRANxITION trial examined the efficacy and safety of switching virologically suppressed patients from nevirapine immediate-release 200mg twice-daily to nevirapine prolonged-release 400mg once-daily.
The antiviral efficacy of Viramune prolonged-release tablets was found to be non-inferior to the older, twice-daily immediate-release 200mg tablet, with a comparable safety and tolerability profile.
The Viramune 400mg once-daily tablet was approved by the US Food and Drug Administration (FDA) earlier this year.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
